CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Hyaluronic acid injected with the new tool. +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01066026
NCT01066026Phase 2Completed

Double-blind, Randomized and Controlled Clinical Trial to Compare Safety and Efficacy of a Metallic Cannula vs a Standard Needle for the Injection of Hyaluronic Acid Gel Dermal Filler (Restylane®) to Treat Nasolabial Folds

Hexsel Dermatology Clinic·interventional·Posted Feb 10, 2010·Updated Oct 1, 2020

In Brief

A Phase 2 clinical trial evaluating hyaluronic acid with metallic cannula or standard needle. and Hyaluronic acid injected with the new tool. for Wrinkles. Completed, enrolled 25 participants across 2 sites.

Detailed Summary

The purpose of this study was to assess the safety and efficacy of a new metallic cannula to inject hyaluronic acid for dermal augmentation in the nasolabial folds compared to standard needle.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWrinkles
CountriesBrazil
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2010
Enrollment StartJul 1, 2009
Primary CompletionJan 1, 2010
Study CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.4 years ago

Interventions

hyaluronic acid with metallic cannula or standard needle.procedure

The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices: * In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit; * In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit. Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula.

Hyaluronic acid injected with the new tool.drug

hyaluronic acid with metallic cannula.